1-Acetyl-5-MeO-DMT

1-Acetyl-5-MeO-DMT
Clinical data
Other names	"Methyl amide 5-MeO-DMT"; 1-Acetyl-5-methoxy-N,N-dimethyltryptamine; 1A-5-MeO-DMT; 1-Ac-5-MeO-DMT; "Example 2-16"
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name 1-[3-[2-(dimethylamino)ethyl]-5-methoxyindol-1-yl]ethanone;
CAS Number	39998-63-5;
PubChem CID	85809049;
ChemSpider	129443806;
ChEMBL	ChEMBL5266842;
Chemical and physical data
Formula	C15H20N2O2
Molar mass	260.337 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N1C=C(C2=C1C=CC(=C2)OC)CCN(C)C;
	InChI InChI=1S/C15H20N2O2/c1-11(18)17-10-12(7-8-16(2)3)14-9-13(19-4)5-6-15(14)17/h5-6,9-10H,7-8H2,1-4H3; Key:FALARLKUFDIOTH-UHFFFAOYSA-N;

1-Acetyl-5-MeO-DMT, also known as "methyl amide 5-MeO-DMT" or as 1-acetyl-5-methoxy-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT.^[2]^[3]^[1] It is the 1-acetyl derivative of 5-MeO-DMT.^[2]^[1] The drug is a prodrug of 5-MeO-DMT with modified pharmacokinetic properties compared to 5-MeO-DMT in rodents.^[2]^[3]^[1] It is assumed to be cleaved into 5-MeO-DMT by amidase enzymes.^[1] Various analogues of 1-acetyl-5-MeO-DMT that are likewise 5-MeO-DMT or dimethyltryptamine (DMT) prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life.^[2]^[3]^[1]^[4] 1-Acetyl-5-MeO-DMT was first described in the literature in a patent by Terran Biosciences in 2023.^[2]^[3]^[1] It has been one of the major prodrug compounds highlighted from the patent.^[2]^[1]